Preview

Артериальная гипертензия

Расширенный поиск

Ассиметричный диметиларгинин в качестве медиатора и маркера развития эндотелиальной дисфункции

https://doi.org/10.18705/1607-419X-2007-13-2-119-127

Полный текст:

Аннотация

Нарушение эндотелий - зависимой вазодилятации является одним из основных эффектов, возникающих при накоплении ассиметричного диметиларгинина (АДМА) и гомоцистеина в организме.
Повышенный уровень АДМА в плазме крови может формироваться при умеренной форме гипергомоцистеинемии (ГГци). В большинстве случаев торможение eNOS иод, влиянием гомоцистеина возникает за счет ассиметричного диметиларгинина (АДМА), накапливающегося в эндотелиоцитах. Механизм этого явления, по-видимому, состоит в том, что гомоцистеин в клетке превращается в S-аденозилгомоцистеин - мощный ингибитор диметилар-гинин-диметиламиногидролазы (ДДАГ). Данные литературы указывают на то, что развитие эндотелиальной дисфункции может зависеть как от сочетания всех этих факторов, так и в отсутствие одного из них.

Об авторе

А. А. Жлоба
Отдел биохимии НИЦ СПбГМУ им. И.П. Павлова
Россия


Список литературы

1. Gokce, N. L-Arginine and Hypertension//J. Nutr.- 2004-.V 134.-P.2807S-2811S.

2.

3. Perticone F., Sciacqua A., Maio R., et al. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension J Am Coll Cardiol.- 2005.- V 46.- P 518-523.

4.

5. Rizzoni D., Porteri E., Castellano M., et al. Endothelial Dysfunction in Hypertension Is Independent From the Etiology and From Vascular Structure// Hypertension.- 1998.- 31.-P. 335-341.

6.

7. Osanai S. M., Matsunaga Т. К. Т., Ishizaka Т., et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level// Heart Vessels.-2003 .-V 18.-P 177-82.

8.

9. Variance P., Leone A., Carver A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure// Lancet.- 1992.- V 339.- P 572-575.

10.

11. Vallance P., Leone A., Calver A., et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis// J Cardiovasc Pharmacol- 1992.- V 20 (suppl 12).- P S60-S62.

12.

13. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance// Clin Chem Lab Med.- 2005.- 43.- P.l 130-1138.

14.

15. Boisvert F.-M., Cфtq J., Boulanger M.-C., and Richard S. A proteomic analysis of arginine methylated protein complexes// Mol Cell Proteomics .- 2003.- V 2.- P 1319-1330.

16.

17. Achan V., Broadhead M., Malaki M., Whitley G., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase// Arterioscler Thromb Vase Biol- 2003.- V 23.-P 1455-1459.

18.

19. Ziegler S., Mittermayer .F, Plank C., et al. Homocysteine-lowering therapy does not affect plasma AD MA concentrations in patients with peripheral artery disease //J Clin Endocrinol Metab.-2005.- V 90.- № 4.- P 2175-2178.

20.

21. Cooke J. P., Asymmetrical dimethylarginine. The ьber marker?// Circulation.- 2004.-V 109.-P 1813-1819.

22.

23. Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia// Vascular Medicine.-2005.-V. 10.- P S27-33.

24.

25. Jonasson T.F., Hedner Т., Hultberg В., Ohlin H. Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease// Eur J Clin Invest.- 2003.- V 33.-P 543-549.

26.

27. Stamler J.S., Simon D.I., Osborne J.A., et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds// Proc Natl Acad Sci U S A.-1992.- V 89.- P. 444-448.

28.

29. Stamler J. S. S-nitrosothiols in the blood roles, amounts, and methods of analysis// Circ. Res.- 2004.- V 94.-P 414-417.

30.

31. Rassaf T. Preik M., Kleinbongard P. Evidence for in vivo transport of bioactive nitric oxide in human plasma //J. Clin. Invest. 2002.-V. 109.-P 1241-1248.

32.

33. Tsuchiya K., Kanematsu Y.,1 Yoshizumi M., et al. Nitrite is an alternative source of NO in vivo //Am J Physiol Heart Circ Physiol- 2005.-V. 288.-P H2163-H2170.

34.

35. Al-Sa'doni H., Ferro A. S-Nitrosothiols: a class of nitric oxide-donor drugs// Clinical Science.-2000.- V 98.-P 507-520.

36.

37. Gow A. J., Farkouh С.R., Munson D. A., et al. Biological significance of nitric oxide-mediated protein modifications// Am J Physiol Lung Cell Mol Physio.- 2004.- V 287.-P L262-L268.

38.

39. Singel D. J., Stamler J. S. Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and s-nitrosohemoglobin// Annual Review of Physiology.- 2005.- V 67.-P 99-145.

40.

41. Stamler J. S., Jaraki O., Osborne J., et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin// Proc Natl Acad Sci U S A.- 1992.- V 89(16).-P 7674-7677.

42.

43. Fujiwara N., Osanai Т., Kamada Т., et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension. Modulation of nitric oxide synthesis by salt intake// Circulation.- 2000.-V 10. P856-861.

44.

45. Yoon Y., Song J., Hong S. H., Kim J. Q. Plasma Nitric Oxide Concentrations and Nitric Oxide Synthase Gene Polymorphisms in Coronary Artery Disease// Clin Chem.- 2000.- V 46.- №10.-P 1626-1630.

46.

47. Hishikawa К. Т., Nakaki Т., Suzuki H, et al. Transmural pressure inhibits nitric oxide release from human endothelium cells. Eur J Pharmacol- 1992.- V 215.- P 329-331.

48.

49. Refsum H., Smith A.D., Ueland P.M. et al. Facts and recommendations about total homocysteine determinations: an expert opinion// Clin. Chem. - 2004. - V 50, №1. - P 3-32.

50.

51. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease// Lancet.- 1999.- V 13.-P. 354-407.

52.

53. Lim A., Sengupta S., McComb M. E., et al. In Vitro and in Vivo Interactions of Homocysteine with Human Plasma Transthyretin//J. Biol. Chem..- 2003.- V 278(50).-P 49707-49713.

54.

55. Jungersten L., Ambring A., Wall B., et al. Both physical fitness and acute exercise regulate nitric oxide formation in healthy humans//J Appl Physiol- 1997.-V 82.-P760-764.

56.

57. Condorelli P., George S. C. In Vivo Control of Soluble Guanylate Cyclase Activation by Nitric Oxide: A Kinetic Analysis/ /Biophysical Journal- 2001.-V 80.-P 2110-2119.

58.

59. Stone, J. R., and M. A. Marietta. Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide// Biochemistry.- 1996.- V. 35.-P 1093-1099.

60.

61. Zhang X., Li H., Jin H., et al. Effects of homocysteine on endothelial nitric oxide production// Am J Physiol Renal Physiol. -2000.- V. 279.-P.F671-F678.

62.

63. Node K., Kitakaze M., Yoshikawa H., et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension// Hypertension.- 1997.-V 30.-P 405-408.

64.

65. Endemann D. H., Schiffrin E. L. Endothelial Dysfunction// J Am Soc Nephrol- 2004.- V 15.- P. 1983-1992.

66.

67. Каминская Л. Ю., Жлоба А.А., Александрова Л.А., Моисеева O.M.Moiseeva, O.M., Эмануэль В.Л., Шляхто Е.В. Влияние донатора NO нитрозотиола глутатиона на уровень окислов азота и малонового диальдегида в крови крыс // Артериальная гипертензия.- 2005.- V П.- №1.- Р 5-9.

68.

69. Shaul, P. W. Anderson, R. G. Role of plasmalemmal caveolae in signal transduction// Am. J. Physiol- 1998.-V 275 P L843-L851.

70.

71. Way M., Parton R. G. M-caveolin, a muscle-specific caveolin-related protein// FEBS Lett. 1995.- V 376.- P108-112.

72.

73. Davies P. F., Polacek D.C., Shi C., Helmke B. P. The convergence of haemodynamics, genomics, and endothelial structure in studies of the focal origin of atherosclerosis// Biorheology.- 2002.- V. 39.- P. 299-306.

74.

75. Liu J., Garcia-Cardena G., Sessa W.C. Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme// Biochemistry.- 1995.- 34.- P. 12333-12340.

76.

77. Liu J., Garcia-Cardena G., Sessa W.C. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization// Biochemistry.- 1996.-V. 35.- P.13277-13281.

78.

79. Liu J., Sessa W. C. Identification of covalently bound amino-terminal myristic acid in endothelial nitric oxide synthase// J Biol Chem. 1994.-V. 269.- №16.- P.l 1691-11694.

80.

81. Osanai Т., Saitoh M., Sasaki S., et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells// Hypertension.- 2003.-42.- P. 985-990.

82.

83. Rubanyi G. M., Freay A. D., Kauser K., et al. Mechanoreception by the endothelium: mediators and mechanisms of pressure - and flow-induced vascular responses// Blood Vessels. 1990.-27.- P 246-257.

84.

85. Lansman J.B., Hallam T.J., Rink T.J. Single stretch-activated ion channel in vascular endothelial cells as mechanotransducers?// Nature.- 1987.- V 325.- P 811-813.

86.

87. Vanauker M. D., Tacy T. A., Nido P. J-d.2 and Cape E. G. Development of a Noninvasive Marker of Wall Shear Stress Effects in Discrete Subaortic Stenosis// Cardiovascular Engineering .-2001.-V.l.-№ 3.-137-146.

88.

89. Shen J., Luscinskas F. W., Connolly A., et al. Fluid shear stress modulates cytosolic free calcium in vascular endothelial cells// Am J Physiol- 1992.- V.262.- P. C384-C390.

90.

91. Schwarz G., Callewaert G., Droogmans G., Nilus B. Shear stress-induced calcium transients in endothelial cells from human umbilical cord veins//J Physiol (Lond).- 1992.-V 458.-P 527-538.

92.

93. Kanai A. J., Strauss H. C., Truskey G. A., et al. Shear stress induces atp-independent transient nitric oxide release from vascular endothelial cells, measured directly with a porphyrinic microsensor// Circulation Research. 1995.-V 77.- P 284-293.

94.

95. Marietta MA. Nitric oxide synthase: aspects concerning structure and catalysis// Cell.-1994-V 78.- P 927-930.

96.

97. Boger R. Asymmtric dimethilarginin (ADMA) and cardiovascular disease: insights from prospective clinical trials// Vascular Medicine.- 2005 .- V 10.- P 19-25.

98.

99. Yildirim A. O., Bulau P., Zakrzewicz D., Kitowska К. Е., et al. Increased Protein Arginine Methylation in Chronic Hypoxia: Role of Protein Arginine Methyltransferases //Am J Respir Cell Mol Biol- 2006.- V. 35.- № 4.- P. 436-443.

100.

101. Brown K. S., Kluijtmans L. A., Young I. S., et al. Genetic evidence that nitric oxide modulates homocysteine: the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia// Arterioscler Thromb Vasc Biol.- 2003.- V 23.- P 1014-1020.

102.

103. Mardsen P.A., Schappert K.T., Chen H.S. Flowers M. et al. Molecular cloning and characterization of human endothelial nitric oxide synthase// FEBS Lett. - 1992. - Vol. 307. - P. 287- 293.

104.

105. Затейщиков Д.А., Чумакова О.С., Затейщикова А.А., Зотова И.В., и др. Генетические предикторы неблагоприятного течения заболевания убольных ишемической болезнью сердца высокого риска по данным 2-летнего наблюдения// Кардиология.- 2004.- 12 .-С 16-22.

106.

107. Shaw G. М., Iovannisci D. M., Yang W., et al. Endothelial nitric oxide synthase (NOS3) genetic variants, maternal smoking, vitamin use, and risk of human orofacial clefts// Am J Epidemiol..-2005.-V 162.-№. 12.-P 1-8.

108.

109. Olsen S.P., Clapham D.E., Davies P.F. Haemodynamic shear stress activates a K+ current in vascular endothelial cells// Nature.- 1988.- V 331.- P.-168-170.

110.

111. McLaughlin Т., M. Stbhlinger, С. Lamendola, F. et al. Plasma Asymmetric Dimethylarginine Concentrations Are Elevated in Obese Insulin-Resistant Women and Fall with Weight Loss//J Clin Endocrin Metab.- V 91.- № 5.- P 1896-1900.

112.

113. Nijveldt R. J., Siroen M. P. C., Teerlink Т., van Leeuwen P. A. M. Elimination of Asymmetric Dimethylarginine by the Kidney and the Liver: A Link to the Development of Multiple Organ Failure?//J. Nutr.- 2004.- V 134.-10.- P 2848S-2852S.

114.

115. Teerlink T. ADMA metabolism and clearance// Vascular Medicine.- 2005.- V 10.- S73-81.

116.

117. Boger R. H., Bode-Boger S. M. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascudar diseases // Seminars in thrombosis and hemostasis.- 2000.-V 26.- № 5.- P. 539-545.

118.

119. Zhloba A.A., Blashko E.L., Bercovich O.A., Chromova N. V. et al. Plasma NO-sinthase productes value and total homocysteine in postinfarct patients// International Congress "Hypertension - from Korotkov to present days".- Saint Petersburg.- September 15 -17 .-2005.- P. 148.

120.


Для цитирования:


Жлоба А.А. Ассиметричный диметиларгинин в качестве медиатора и маркера развития эндотелиальной дисфункции. Артериальная гипертензия. 2007;13(2):119-127. https://doi.org/10.18705/1607-419X-2007-13-2-119-127

For citation:


Zhloba A.A. ADMA as a marker and mediator of endothelial dysfunction progression. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(2):119-127. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-2-119-127

Просмотров: 108


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)